Cargando…
Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3
CONTEXT: Molecular testing has improved risk stratification and increased nonoperative management for patients with indeterminate thyroid nodules, but data on the long-term outcomes of current molecular tests Afirma Gene Sequencing Classifier (GSC) and Thyroseq v3 are limited. OBJECTIVE: To determin...
Autores principales: | Kim, Na Eun, Raghunathan, Rajam S, Hughes, Elena G, Longstaff, Xochitl R, Tseng, Chi-Hong, Li, Shanpeng, Cheung, Dianne S, Gofnung, Yaroslav A, Famini, Pouyan, Wu, James X, Yeh, Michael W, Livhits, Masha J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438873/ https://www.ncbi.nlm.nih.gov/pubmed/36995878 http://dx.doi.org/10.1210/clinem/dgad181 |
Ejemplares similares
-
PSAT213 Intrathyroidal Parathyroid Adenoma Diagnosed on Thyroseq v2
por: Tsai, Karen, et al.
Publicado: (2022) -
Real-World Performance of the Afirma Genomic Sequencing Classifier (GSC)—A Meta-analysis
por: Nasr, Christian E, et al.
Publicado: (2022) -
Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis
por: Silaghi, Cristina Alina, et al.
Publicado: (2021) -
Comparison of Afirma GEC and GSC to Nodules Without Molecular Testing in Cytologically Indeterminate Thyroid Nodules
por: Polavarapu, Preethi, et al.
Publicado: (2021) -
LBSAT255 Real World Performance Of The Afirma Genomic Sequencing Classifier (GSC) - A Meta-analysis
por: Nasr, Christian E, et al.
Publicado: (2022)